Tyra biosciences doses first patient in phase 2 study of tyra-300 in low-grade intermediate risk non-muscle invasive bladder cancer (surf302)

-tyra-300 is the only orally administered investigational agent in clinical development for ir nmibc- -initial 3-month complete response (cr) data expected to be reported in 1h 2026- carlsbad, calif. , june 30, 2025 /prnewswire/ -- tyra biosciences, inc. (nasdaq: tyra), a clinical-stage biotechnology company focused on developing next-generation precision medicines that target large opportunities in fibroblast growth factor receptor (fgfr) biology, announced today that the first patient has been dosed in the phase 2 surf302 clinical trial of tyra-300 in low-grade, intermediate risk non-muscle invasive bladder cancer (ir nmibc).
TYRA Ratings Summary
TYRA Quant Ranking